杜仲壮骨胶囊联合雷洛昔芬治疗绝经后骨质疏松症临床研究  

Clinical study of Duzhong Zhuanggu capsule combined with raloxifene in the treatment of postmenopausal osteoporosis

作　　者：戴少川 DAI Shaochuan(Department of Orthopedics,the First Affiliated Hospital of Xiamen University,Xiamen,361000,China)

机构地区：[1]厦门大学附属第一医院骨伤科,福建厦门361000

出　　处：《中国骨质疏松杂志》2018年第11期1489-1492,共4页Chinese Journal of Osteoporosis

摘　　要：目的探索杜仲壮骨胶囊联合雷洛昔芬治疗绝经后骨质疏松症临床疗效。方法 158例绝经后骨质疏松症患者随机分为治疗组(n=79)和对照组(n=79)。对照组给予雷洛昔芬治疗,治疗组给予杜仲壮骨胶囊联合雷洛昔芬治疗,为期治疗12个月。检测治疗前后两组患者股骨颈、腰椎及髋部的骨密度,同时测定血清骨代谢指标:骨碱性磷酸酶(BALP)、I型原胶原N-端前肽(PINP)和血清I型胶原交联C-末端肽(S-CTX)、碱性磷酸酶(ALP)、骨钙素(BGP)的水平,记录两组治疗总有效率和药物不良反应。结果治疗组的治疗总有效率为93.67%,而对照组的为78.48%,两组比较差异有统计学意义(P<0.05)。治疗12个月,两组股骨颈、髋部及腰椎密度都有不同程度的升高,其中治疗组骨密度变化更明显,和对照组比较差异有明显的统计学意义(P<0.05);同时各组血清S-CTX、PINP和ALP水平均降低,BALP和BGP水平均升高,而治疗组改变更明显,两组比较差异有明显的统计学意义(P<0.05)。两组患者药物不良反应比较差异有明显的统计学意义(P>0.05)。结论杜仲壮骨胶囊联合雷洛昔芬治疗绝经后骨质疏松症,安全有效,较雷洛昔芬单独治疗效果更佳。Objective To explore the clinical efficacy of Duzhong Zhuanggu capsule combined with raloxifene in the treatment of postmenopausal osteoporosis. Methods 158 cases of postmenopausal osteoporosis were randomly divided into treatment group (n=79) and control group (n=79). The control group was treated with raloxifene, and the treatment group was treated with Duzhong Zhuanggu capsule combined with raloxifene for 12 months. The bone mineral density of the femoral neck, lumbar spine and hip, the levels of serum bone alkaline phosphatase (BALP), type I procollagen N-terminal propeptide (PINP) , serum type I collagen cross-linked C-terminal peptide (S-CTX), alkaline phosphatase (ALP) and osteocalcin (BGP) were measured before and after treatment. The total effective rate and adverse drug reactions were recorded in both groups. Results The total effective rate of the treatment group was 93.67%, while that of the control group was 78.48%, there was significant difference between the two groups (P<0.05). After 12 months treatment, the BMD of the femoral neck, hip and lumbar in both groups increased to some extent. The changes of bone mineral density in the treatment group were more obvious than those in the control group (P<0.05). At the same time, the levels of serum S-CTX, PINP and ALP in each group were decreased, the levels of BALP and BGP were increased, while the changes in the treatment group were more obvious. There was significant difference between the two groups (P<0.05). The difference between two groups of patients on adverse drug reactions was statistically significant (P>0.05). Conclusion Duzhong Zhuanggu capsule combined with raloxifene in the treatment of postmenopausal osteoporosis is safe and effective, which is better than raloxifene alone.

关 键 词：绝经后骨质疏松症 骨密度 杜仲壮骨胶囊 雷洛昔芬 

分 类 号：R453[医药卫生—治疗学]